ESMO Breast Cancer 2025 Industry Satellite Symposium
Scopri il test Oncotype DX Breast Recurrence Score®: progettato e sviluppato in modo unico per portare chiarezza nelle decisioni terapeutiche.
Loading component...
Loading component...
Loading component...
Altri webinar ed eventi registrati
Insights & perspectives from a centralized laboratory in genomic testing
Listen Rick Baehner, MD and Helen Bailey, MD share insights of a centralized laboratory & give perspectives how expertise in genomic testing will...
The pathologist's impact on clinical practice & patients' lives
Hear Prof. Giancarlo Pruneri of the University of Milan providing his insights on the importance of analytical work and the critical need to...
The development of the Oncotype DX Breast Recurrence Score® test in breast cancer
Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the analytical validation and the key clinical attributes of the the Oncotype...
Clinical validation of the Oncotype DX Breast Recurrence Score® test in breast cancer
Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the clinical validation of the Oncotype DX® test in TAILORx (N0 population)...
Future of the Oncotype DX Breast Recurrence Score® test in breast cancer
Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the Oncotype DX® test in ongoing trials.
Cancer Network Podcast, S1 Ep17
I dottori Alison Laws, Philip Poorvu e Sara Hurvitz discutono l'utilità del test Oncotype DX Breast Recurrence Score per le pazienti con tumore al seno HR+, HER2-. e linfonodi positivi.
Rimaniamo in contatto
Hai domande sul test Oncotype DX?
